The unintended effects of a boxed warning

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 9, 2009, Pages

  Ceilley, Roger ^a   Eisenthal, Andrew ^b  

^a UNIVERSITY OF IOWA   (United States)

^b BUCKNELL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR;

ARTICLE; ATOPIC DERMATITIS; DISEASE CONTROL; DRUG LABELING; HEALTH CARE PERSONNEL; HEALTH SURVEY;

EID: 77954247749     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Code of Federal Regulations. Title 21: Food and Drugs. Volume 4, Part 201 57(e). http://a257.g.akamaitech.net/7/257/2422/14mar20010800/edocket.access.gpo.gov/cfr_2002/aprqtr/pdf/21cfr201.57.pdf. Accessed December 9, 2007.
2. Beach JE, Faich GA, Bormel FG, et al. Boxed warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53:403-411.
3. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the boxed warning half empty or half full? Pharmacoepidemilo Drug Saf. Epub 18 Nov 2005 http://www3.interscience.wiley.com/cgi-bin/fulltext/112141666/PDFSTART. Accessed December 9, 2007
4. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17.
5. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997; 10(3):136-145.
6. Want to Treat Eczema? Beware of Cancer. www.CNN.com. Accessed January 19,2006
7. Anonymous. New warnings for two eczema drugs. www.fda.gov/fdac/departs/2006/206_ipd.html#eczema. Accessed April 2, 2006
8. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol. 2003;149(5):960-967.
9. Tran C, Lübbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology. 2005;211(4):341-347.
10. Naylor M, Elmets C, Jaracz E, et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat. 2005;16(3):149-153.
11. Koo JY, Fleischer AB Jr, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005;53(2 Suppl 2):S195-S205.
12. Hanifin JM, Paller AS, Eichenfield L, et al. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to four years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53(2 Suppl 2):S186-S194.
13. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117(1):e118-e128.
14. Billich A, Aschauer H, Aszódi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269(1):29-35.
15. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816.
16. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222-230.
17. Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology. 2007;215(Suppl 1):27-44.